University of Tx Md Anderson Can Ctr

Organization

People

Sources: reporter.nih.gov

Grants and prizes

  • National Cancer Institute

    N01, RANK Ligand Inhibition - a Potential Chemoprevention Strategy for Women at High Genetic Risk of Breast Cancer HHSN2612015000181 TO: HHSN26100009 PP: 9/17/18 to 3/16/2021, 26120150001, $643K, 2018–2021

  • National Cancer Institute

    N01, OPTIMIZATION OF DOSING REGIMENS OF SULINDAC IN COMBINATION WITH ERLOTINIB FOR SMALL INTESTINAL AND COLON CANCER PREVENTION, 75N91019D00, $854K, 2019–2022

  • National Cancer Institute

    N01, TIME-RESTRICTED FEEDING FOR PANCREATIC CANCER PREVENTION, 75N91024D00, $552K, 2024–2026

  • National Cancer Institute

    R01, The Impact of Biologic Aging on Immunity-Related Cervical Cancer Outcome Disparities Among Women Living with HIV in Zambia, R01CA284623, $68.8K, 2023–2028, Sep 17, 2026

  • National Cancer Institute

    U01, Circulating Biomarkers and Imaging for Early Detection of Pancreatic Cancer, U01CA214263, $978K, 2018–2029, Sep 17, 2026

  • National Institute on Aging

    R56, Telomerase in Alzheimer’s Disease Pathogenesis and Treatment, R56AG093636, $687K, 2026–2027, Sep 16, 2026

  • National Cancer Institute

    R37, Standardizing Patient-Centered Treatment Protocols for Breast and Gynecologic Cancer Survivors with Sexual Dysfunction Incorporating Longitudinal Vaginal Microbiome Changes, R37CA316264, $374K, 2026–2031, Sep 14, 2026

  • National Cancer Institute

    K99, The role of TET2 clonal hematopoiesis on solid tumor immunology, K99CA315451, $135K, 2026–2028, Sep 11, 2026

  • National Heart, Lung, and Blood Institute

    K23, Advancing Sustainable Obesity Care: Integrating Food is Medicine with GLP-1 Receptor Agonists, K23HL186120, $104K, 2026–2031, Sep 3, 2026

  • National Institute on Aging

    R61, Development of a Nonhuman Primate Infrastructure for Interdisciplinary Research on Perimenopause and Aging, R61AG102807, $629K, 2026–2028, Sep 2, 2026

  • National Institute on Aging

    R21, Modeling age-dependent HSP90 decline and genome instability in mammals, R21AG103389, $451K, 2026–2028, Aug 26, 2026

  • National Cancer Institute

    R37, Together stronger: A family-centered lifestyle intervention for Black prostate cancer survivors and their caregivers, R37CA303326, $681K, 2025–2030, Aug 20, 2026

  • National Institute on Aging

    K01, Baboon model of chemotherapy-related cognitive impairment and accelerated aging, K01AG078411, $184K, 2022–2027, Aug 14, 2026

  • National Cancer Institute

    UG1, iCAN PREVENT: MD Anderson International Cancer Prevention Clinical Trials Consortium, UG1CA242609, $734K, 2019–2031, Aug 11, 2026

  • National Cancer Institute

    U01, Blood-Based Biomarkers for Personalized Risk Assessment of Breast and Ovarian Cancer, U01CA282216, $672K, 2023–2028, Aug 7, 2026

  • National Heart, Lung, and Blood Institute

    R01, Deciphering the role of GFPT2 in radiation-induced cardiovascular disease, R01HL179815, $718K, 2025–2029, Jul 31, 2026

  • National Institute on Minority Health and Health Disparities

    R21, Driving Wellness: A Feasibility Trial of a Multi-Level Health Behavior Intervention for Truck Drivers, R21MD021573, $261K, 2026–2028, Jul 30, 2026

  • National Cancer Institute

    K01, Decoding Mosaic Chromosomal Alterations in Lymphoid Malignancy Risk and Outcomes, K01CA297060, $192K, 2025–2030, Jul 28, 2026

  • National Institute on Aging

    K01, Impact and therapeutic effects of selective TERT activation in Alzheimers disease, K01AG088489, $101K, 2026–2031, Jul 28, 2026

  • National Cancer Institute

    R01, Multi-ancestry study of mammographic density, R01CA317515, $718K, 2026–2031, Jul 23, 2026

Sources: reporter.nih.gov